Topiramate: Long-Term Maintenance of Weight Loss Induced by a Low-Calorie Diet in Obese Subjects

University of Milan, Milano, Lombardy, Italy
Obesity research (Impact Factor: 4.95). 10/2004; 12(10):1658-69. DOI: 10.1038/oby.2004.206
Source: PubMed


To examine the safety and efficacy of topiramate (TPM) for maintaining weight following a low-calorie diet.
Obese subjects (30 < or = BMI < 50 kg/m(2)) 18 to 75 years old received a low-calorie diet for 8 weeks. Those who lost > or =8% of their initial weight received TPM (96 or 192 mg/d) or placebo; all were on a lifestyle modification plan. Sixty weeks of medication were planned. Sponsor ended study early to develop a new controlled-release formulation with the potential to enhance tolerability and simplify dosing in this patient population. Efficacy was analyzed in subjects who completed 44 weeks of treatment before study termination.
Of the 701 subjects enrolled, 80% lost > or =8% of their initial body weight and were randomized; 293 were analyzed for efficacy. Most withdrawals were due to premature termination of the study. Subjects receiving TPM lost 15.4% (96 mg/d) and 16.5% (192 mg/d) of their enrollment weight by week 44, compared with 8.9% in the placebo group (p < 0.001). Subjects on TPM continued to lose weight after the run-in, whereas those on placebo regained weight. Significantly more TPM subjects lost 5%, 10%, or 15% of their randomization weight than placebo. Most adverse events were related to the central nervous system.
During a treatment period of 44 weeks, TPM was generally well tolerated, and subjects maintained weight loss initially achieved by a low-calorie diet-and produced additional clinically significant weight loss beyond that achieved by a low-calorie diet.

Full-text preview

Available from:
  • Source
    • "ng anecdotal reports of weight loss occur - ring in patients with epilepsy , it was evaluated as a potential antiobesity drug in clinical trials [ Astrup et al . 2004a ] . Topiramate produced a very substantial weight reduction in subjects with obesity , particularly when administered after initial weight loss induced with a very low energy diet [ Astrup et al . 2004b ] , but an indica - tion as a monotherapy for obesity was aban - doned due to dose - dependent neuropsychiatric and cognitive adverse events , such as memory and concentration impairment , language diffi - culties and mood changes [ Nathan et al . 2011 ; Sommer et al . 2013 ] . Although the exact mecha - nism of action for weight loss w"
    [Show abstract] [Hide abstract]
    ABSTRACT: Public health initiatives focused on obesity prevention and lifestyle intervention programmes for patients with obesity have struggled to contain the obesity epidemic to date. In recent years, antiobesity drug therapies have had a limited role in clinical treatment algorithms for patients with obesity. Indeed, a number of high-profile antiobesity drug suspensions have markedly impacted upon the landscape of obesity pharmacotherapy. In this review, we discuss the advent of an increasing array of pharmacotherapeutic agents, which are effective both in inducing weight loss and in maintaining weight loss achieved by lifestyle measures. The development of these drugs as antiobesity agents has followed varying paths, ranging from lorcaserin, a selective serotonin agent, exploiting the beneficial central actions of fenfluramine but without the associated systemic side effects, to liraglutide, a gut hormone already used as a glucose-lowering drug but with appetite-suppressant properties, or the novel drug combination of phentermine/topiramate, two 'old' drugs used in lower doses than with previous therapeutic uses, resulting in an additive effect on weight loss and fewer side effects. We summarize the key findings from recent randomized controlled trials of these three drugs. Although these agents lead to clinically important weight loss when used as monotherapy, the use of antiobesity drugs as adjunctive therapy post intensive lifestyle intervention could prove to be the most successful strategy. Moreover, a progressive approach to obesity pharmacotherapy perhaps offers the best opportunity to finally address the obesity crisis on a mass scale.
    Therapeutic Advances in Chronic Disease 05/2014; 5(3):135-148. DOI:10.1177/2040622314522848
  • Source
    • "Several clinical studies showed that treatment with TPM is associated with significant weight loss of the patients, in contrast with the effects of traditional mood stabilizers generally leading to body weight gain [3] [4] [5] [6]. In a recent study following 307 obese subjects with type 2 diabetes over 1 year, TPM was effective for weight reduction and improvement in glycemic control [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Topiramate (Topamax), primarily prescribed against epilepsy, was reported to reduce body weight and to ameliorate glycemic control in obese patients with diabetes. In rodent models of obesity and diabetes, topiramate treatment counteracts hyperglycemia and increases insulin levels upon glucose tolerance test. These observations suggest that topiramate might exert direct action on insulin secreting cells, in particular regarding obesity associated beta-cell dysfunction. In this study, INS-1E beta-cells were exposed for 3 days to the fatty acid oleate (0.4mM) and concomitantly treated with therapeutic concentrations of topiramate before measurements of insulin secretion and metabolic parameters. In healthy cells, topiramate had no acute or chronic effects on insulin release. Exposure of INS-1E cells to oleate for 3 days increased insulin release at basal 2.5mM glucose and blunted the response to stimulatory glucose concentration (15mM). Such lipotoxic effects were associated with impaired mitochondrial function, as evidenced by partial loss of resting mitochondrial membrane potential and reduced hyperpolarization in response to glucose. Oil-red-O staining and triglyceride measurements revealed lipid accumulation in oleate treated cells. Topiramate treatment counteracted oleate-induced lipid load and partially protected against mitochondrial membrane dysfunction. In particular, topiramate restored glucose stimulated insulin secretion, essentially by maintaining low insulin release at basal glucose. Topiramate increased expression of the nutrient sensor PPARalpha and of the mitochondrial fatty acid carrier CPT-1, correlating with enhancement of beta-oxidation rate. The data demonstrate that a drug originally used as mood stabilizer exerts a direct action on beta-cells, protecting against lipid-induced dysfunction.
    Biochemical Pharmacology 11/2006; 72(8):965-73. DOI:10.1016/j.bcp.2006.07.013 · 5.01 Impact Factor

Show more